Pyxis Oncology

PYXS · NASDAQ

$1.84+$0.08 (+4.55%)TodayMarket closed · Oct 20, 7:55 PM ET

Prev close $1.76

PYXS analyst rating

BuyConsensus of 8 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy8
Hold0
Underperform0
Sell0

12-month price target · 11 analysts

Average $8.61 (+368.1% upside)

Low: $6.06
Now: $1.84
High: $19.95

Upgrades and downgrades

The latest rating actions, newest first

PYXS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wedbush	Sep 10, 2026	Maintains	Outperform	$6.00 → $8.00	39%
HC Wainwright & Co.	Sep 10, 2026	Maintains	Buy	$7.00 → $8.00	43%
Wells Fargo	Sep 9, 2026	Maintains	Overweight	$12.00 → $19.00	54%
HC Wainwright & Co.	Aug 18, 2026	Maintains	Buy	$7.00	43%
Wells Fargo	Aug 3, 2026	Initiates	Overweight	$12.00	54%
Leerink Partners	Jul 2, 2026	Maintains	Outperform	$9.00 → $7.00	17%
Wedbush	May 5, 2026	Initiates	Outperform	$6.00	39%
Stifel	Mar 24, 2026	Maintains	Buy	$9.00 → $8.00	33%
HC Wainwright & Co.	Mar 24, 2026	Maintains	Buy	$7.00	43%
RBC Capital	Dec 19, 2025	Maintains	Outperform	$8.00 → $5.00	49%

The case for and against

Updated Oct 21, 2026

Bull case

Pyxis Oncology is attractive because MICVO has shown differentiated anti-tumor activity in a heavily pretreated 2L+ R/M HNSCC population, with a 36% confirmed objective response rate, 94% disease control rate, rapid responses, and a median progression-free survival of 6.2 months. The breadth of activity across HPV-positive and HPV-unrelated disease, plus responses after prior EGFR inhibitor and taxane exposure, supports the view that EDB+FN is a tractable ADC target and that MICVO could be positioned ahead of other late-stage options. Importantly, the dose-capping strategy improved the benefit-risk profile with lower treatment-related discontinuations at 14.3% and no treatment-related deaths, while the company’s upcoming 1H27 overall survival update offers a key catalyst if the early 79% 12-month survival probability is sustained.

Bear case

Pyxis Oncology is a high-risk, pre-commercial oncology company with no revenue and a 2Q26 net loss of $0.40 per diluted share, worse than the $0.33 consensus loss, underscoring continued dependence on external capital. Its investment case hinges almost entirely on MICVO, but the drug still faces material clinical, regulatory, manufacturing, and commercial risk, and the reported 25% confirmed ORR in just 1/4 post-EGFRi patients is too limited to validate efficacy. Although cash and short-term investments were $33M and a July private placement added about $50M in gross proceeds, the company only expects funding into 2Q27, leaving dilution and development failure as central concerns.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.